Bio-Rad Laboratories, Inc. | Mid-cap | Healthcare
$250.08
0.00%
| Bio-Rad Stock Comparison:
Bio-Rad vs Abbott LaboratoriesBio-Rad vs Boston ScientificBio-Rad vs MasimoBio-Rad vs Globus MedicalBio-Rad vs Bio-Rad LaboratoriesBio-Rad vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.6B
Gross Profit 1.4B 53.73%
Operating Income 269.0M 10.48%
Net Income -1.8B -71.86%
EPS (Diluted) -$65.36

Balance Sheet Metrics

Total Assets 9.4B
Total Liabilities 2.8B
Shareholders Equity 6.6B
Debt to Equity 0.43

Cash Flow Metrics

Operating Cash Flow -2.2B
Free Cash Flow 266.2M

Revenue & Profitability Trend

Bio-Rad Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 2.6B 2.7B 2.8B 2.9B 2.5B
Cost of Goods Sold 1.2B 1.2B 1.2B 1.3B 1.1B
Gross Profit 1.4B 1.4B 1.6B 1.6B 1.4B
Research & Development 295.9M 247.4M 256.9M 260.6M 217.8M
Selling, General & Administrative 814.0M 841.7M 827.8M 877.1M 798.8M
Other Operating Expenses 0 0 7.5M 0 0
Total Operating Expenses 1.1B 1.1B 1.1B 1.1B 1.0B
Operating Income 269.0M 337.8M 475.1M 500.3M 421.3M
Pre-tax Income -2.3B -850.1M -4.7B 5.4B 4.9B
Income Tax -498.3M -212.8M -1.1B 1.2B 1.1B
Net Income -1.8B -637.3M -3.6B 4.3B 3.8B
EPS (Diluted) -$65.36 -$21.82 -$121.79 $140.56 $126.20

Income Statement Trend

Bio-Rad Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 3.0B 3.0B 3.2B 2.0B 2.1B
Non-Current Assets 6.3B 9.3B 10.3B 15.8B 10.8B
Total Assets 9.4B 12.3B 13.5B 17.8B 13.0B
Liabilities
Current Liabilities 467.8M 522.8M 568.7M 680.9M 631.5M
Non-Current Liabilities 2.3B 3.0B 3.3B 3.4B 2.5B
Total Liabilities 2.8B 3.6B 3.9B 4.1B 3.1B
Equity
Total Shareholders Equity 6.6B 8.7B 9.6B 13.7B 9.9B

Balance Sheet Composition

Bio-Rad Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -1.8B -637.3M -3.6B 4.3B 3.8B
Operating Cash Flow -2.2B -853.6M -5.0B 5.6B 5.0B
Investing Activities
Capital Expenditures -165.5M -156.5M -112.6M -133.7M -108.5M
Investing Cash Flow -136.8M 20.2M -1.2B -797.4M -73.3M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -238.0M -444.1M 956.0M -76.1M -543.2M
Free Cash Flow 266.2M 218.3M 80.3M 535.7M 476.4M

Cash Flow Trend

Bio-Rad Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3.83
Price to Book 1.03
Price to Sales 2.69
PEG Ratio -0.02

Profitability Ratios

Profit Margin -85.16%
Operating Margin 9.72%
Return on Equity -27.52%
Return on Assets 1.55%

Financial Health

Current Ratio 5.99
Debt to Equity 20.50
Beta 0.94

Per Share Data

EPS (TTM) -$76.53
Book Value per Share $241.72
Revenue per Share $90.53

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
bio.b 6.8B -3.83 1.03 -27.52% -85.16% 20.50
Abbott Laboratories 231.9B 17.31 4.75 30.65% 31.89% 27.09
Boston Scientific 149.9B 73.94 6.75 9.50% 11.58% 52.16
Masimo 9.1B 129.16 9.63 -25.07% -23.25% 72.01
Globus Medical 7.8B 43.14 1.91 4.63% 7.39% 2.27
Bio-Rad Laboratories 6.4B -3.60 0.97 -27.52% -85.16% 20.50

Financial data is updated regularly. All figures are in the company's reporting currency.